CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Anti-Beta Interferon (PF-06823859)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05192200
NCT05192200Phase 2Completed
CompareCT.gov

AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.

Pfizer·interventional·Posted Jan 14, 2022·Updated Feb 6, 2025

In Brief

A Phase 2 clinical trial evaluating Anti-Beta Interferon (PF-06823859) for Dermatomyositis. Completed, enrolled 24 participants across 25 sites in 4 countries.

Detailed Summary

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatomyositis
CountriesHungary, Poland, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 14, 2022
Enrollment StartDec 20, 2021
Primary CompletionNov 20, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.5 years ago

Interventions

Anti-Beta Interferon (PF-06823859)drug

IV infusion